NCT04833504View on ClinicalTrials.gov

Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma

CompletedOBSERVATIONAL
Enrollment

39

Participants

Timeline

Start Date

September 22, 2018

Primary Completion Date

September 22, 2023

Study Completion Date

October 1, 2024

Conditions
Diffuse Large B-cell LymphomaMantle Cell LymphomaTransformed Follicular LymphomaPrimary Mediastinal Large B-cell Lymphoma
Interventions
BIOLOGICAL

CD19 CAR-T Expressing IL7 and CCL19

A fourth generation CD19 targeting CAR-T expressing IL7 and CCL19

Trial Locations (1)

310000

Hui Liu, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT04833504 - Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma | Biotech Hunter | Biotech Hunter